Heparanase and hepatocellular carcinoma: Promoter or inhibitor?

被引:15
|
作者
Dong, Shuo [1 ]
Wu, Xiong-Zhi [1 ]
机构
[1] Tianjin Med Univ Canc Inst & Hosp, Zhong Shan Men In Patient Dept, Tianjin 300171, Peoples R China
基金
中国国家自然科学基金;
关键词
Apoptosis; Heparanase; Heparan sulphate; Hepatocellular carcinoma; Infection; Metastasis; FIBROBLAST-GROWTH-FACTOR; HEPATITIS-C VIRUS; MESSENGER-RNA EXPRESSION; ENVELOPE GLYCOPROTEIN E2; ACTIVATED PROTEIN-KINASE; SULFATE PROTEOGLYCANS; TUMOR-GROWTH; QUANTITATIVE-ANALYSIS; CANCER PROGRESSION; GENE-EXPRESSION;
D O I
10.3748/wjg.v16.i3.306
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Heparan sulphate proteoglycans (HSPGs) consist of a core protein and several heparan sulphate (HS) side chains covalently linked. HS also binds a great deal of growth factors, chemokines, cytokines and enzymes to the extracellular matrix and cell surface. Heparanase can specially cleave HS side chains from HSPGs. There are a lot of conflicting reports about the role of heparanase in hepatocellular carcinoma (HCC). Heparanase is involved in hepatitis B virus infection and hepatitis C virus infection, the activation of signal pathways, metastasis and apoptosis of HCC. Heparanase is synthesized as an inactive precursor within late endosomes and lysosomes. Then heparanase undergoes proteolytic cleavage to form an active enzyme in lysosomes. Active heparanase translocates to the nucleus, cell surface or extracellular matrix. Different locations of heparanase may exert different activities on tumor progression. Furthermore, enzymatic activities and non-enzymatic activities of heparanase may play different roles during HCC development. The expression level of heparanase may also contribute to the discrepant effects of heparanase. Growth promoting as well as growth inhibiting sequences are contained within the tumor cell surface heparan sulfate. Degrading different HSPGs by heparanase may play different roles in HCC. Systemic studies examining the processing, expression, localization and function of heparanase should shed a light on the role of heparanase in HCC. (C) 2010 Baishideng. All rights reserved.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 50 条
  • [41] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    国际感染病学(电子版), 2015, (01) : 35 - 38
  • [42] Promoter Methylation of SFRP3 Is Frequent in Hepatocellular Carcinoma
    Lin, Ya-Wen
    Shih, Yu-Lueng
    Lien, Gi-Shih
    Suk, Fat-Moon
    Hsieh, Chung-Bao
    Yan, Ming-De
    DISEASE MARKERS, 2014, 2014
  • [43] Effect of VEGF promoter polymorphism on the prognosis of patients with hepatocellular carcinoma
    Park, J. W.
    Kong, S. Y.
    Park, J. E.
    Lee, J. A.
    Park, K. W.
    Kim, C. M.
    LIVER INTERNATIONAL, 2006, 26 : 61 - 61
  • [44] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    国际感染病学(电子版), 2016, (04) : 129 - 132
  • [45] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    InfectionInternational(ElectronicEdition), 2012, 1 (01) : 14 - 24
  • [46] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    国际感染病学(电子版), 2016, (01) : 35 - 38
  • [47] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    国际感染病学(电子版), 2016, (03) : 97 - 100
  • [48] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    国际感染病学(电子版), 2018, (01) : 37 - 40
  • [49] Hepatitis B Virus S Promoter Deletion in Hepatocellular Carcinoma
    Su-zhen Jiang
    Jia-jia Zheng
    Xiang-Mei Chen
    Ting Zhang
    Qiang Xu
    Hui Zhuang
    Feng-min Lu
    Infection International, 2015, 4 (04) : 125 - 128
  • [50] Lacking of TERT Promoter Mutation in Fibrolamellar Hepatocellular Carcinoma (FLC)
    Salib, Christian
    Zhu, Hongfa
    Sun, Katherine
    Dong, Xiang
    Fallon, John T.
    Zhong, Minghao
    MODERN PATHOLOGY, 2018, 31 : 648 - 648